Evidence map›Paper›PMID 34347945›Full record

Trial reportArthritis & rheumatology (Hoboken, N.J.)2022

Activated Peripheral Blood B Cells in Rheumatoid Arthritis and Their Relationship to Anti-Tumor Necrosis Factor Treatment and Response: A Randomized Clinical Trial of the Effects of Anti-Tumor Necrosis Factor on B Cells.

Nida Meednu, Jennifer Barnard, Kelly Callahan, Andreea Coca, Bethany Marston, Ralf Thiele, Darren Tabechian, Marcy Bolster, Jeffrey Curtis, Meggan Mackay and 8 more

Registry-linked trialOpen access · greenAbstract readClinical Trial, Phase IVMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Arthritis & rheumatology (Hoboken, N.J.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00837434 (A Partially Blinded, Randomized, Multi-Center, Phase IV Trial to Evaluate Mechanism of Action of Anti-TNF Agents in Rheumatoid Arthritis), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00837434 phase4completednot on this map

A Partially Blinded, Randomized, Multi-Center, Phase IV Trial to Evaluate Mechanism of Action of Anti-TNF Agents in Rheumatoid Arthritis

TypeinterventionalSponsorNational Institute of Allergy and Infectious Diseases (NIAID)Ran2009 to 2014Enrolled63ConditionsRheumatoid ArthritisArmsEtanercept, Adalimumab
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Precision medicine in rheumatoid arthritis.Best practice & research. Clinical rheumatology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 8 institutions in 1 country.

Nida MeednuUniversity of Rochester Medical Center, Rochester, New York.ORCID 0000-0002-2868-3339
Jennifer BarnardUniversity of Rochester Medical Center, Rochester, New York.
Kelly CallahanUniversity of Rochester Medical Center, Rochester, New York.
Andreea CocaUniversity of Rochester Medical Center, Rochester, New York.
Bethany MarstonUniversity of Rochester Medical Center, Rochester, New York.
Ralf ThieleUniversity of Rochester Medical Center, Rochester, New York.
Darren TabechianUniversity of Rochester Medical Center, Rochester, New York.
Marcy BolsterMedical University of South Carolina, Charleston.
Jeffrey CurtisUniversity of Alabama at Birmingham.
Meggan MackayFeinstein Institute for Medical Research, Manhasset, New York.
Jonathan GrafUniversity of California, San Francisco.
Richard KeatingUniversity of Chicago, Chicago, Illinois.
Edwin SmithMedical University of South Carolina, Charleston.
Karen BoyleRho Federal Systems Division, Chapel Hill, North Carolina.
Lynette Keyes-ElsteinRho Federal Systems Division, Chapel Hill, North Carolina.
Beverly WelchNational Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland.
Ellen GoldmuntzNational Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland.
Jennifer H AnolikUniversity of Rochester Medical Center, Rochester, New York.ORCID 0000-0002-1450-1549
University of Rochester Medical Center · USMedical University of South Carolina · USNational Institute of Allergy and Infectious Diseases · USRho (United States) · USFeinstein Institute for Medical Research · USUniversity of Alabama at Birmingham · USUniversity of California, San Francisco · USUniversity of Chicago · US

Funding

Transplantation GroupUM2AI117870 · NIAID · RHO FEDERAL SYSTEMS DIVISION, INC. · PI DAVID, GLORIA · 2015 to 2023
$208.1M
Role of B Cells in Synovial Inflammation & LN Remodeling in RA ArthritisP01AI078907 · NIAID · UNIVERSITY OF ROCHESTER · PI ANOLIK, JENNIFER HOWITT · 2010 to 2014
$10.8M
Translational Research Project Effector and Regulatory B cells in SLEU19AI056390 · NIAID · UNIVERSITY OF ROCHESTER · PI FOWELL, DEBORAH J · 2003 to 2013
$8.9M
B-Cell Tolerance Mechanisms in Human SLER01AI077674 · NIAID · UNIVERSITY OF ROCHESTER · PI ANOLIK, JENNIFER HOWITT · 2009 to 2013
$2.0M
National Institute of Allergy and Infectious Diseases U19 AI563262NIAID NIH HHS P01 AI078907NIAID NIH HHS R01 AI077674NIAID NIH HHS U19 AI056390NIAID NIH HHS UM2 AI117870
6 · The paper itself

Abstract

objectiveB cells can become activated in germinal center (GC) reactions in secondary lymphoid tissue and in ectopic GCs in rheumatoid arthritis (RA) synovium that may be tumor necrosis factor (TNF) and lymphotoxin (LT) dependent. This study was undertaken to characterize the peripheral B cell compartment longitudinally during anti-TNF therapy in RA.

methodsParticipants were randomized in a 2:1 ratio to receive standard dosing regimens of etanercept (n = 43) or adalimumab (n = 20) for 24 weeks. Eligible participants met the American College of Rheumatology 1987 criteria for RA, had clinically active disease (Disease Activity Score in 28 joints >4.4), and were receiving stable doses of methotrexate. The primary mechanistic end point was the change in switched memory B cell fraction from baseline to week 12 in each treatment group.

resultsB cell subsets remained surprisingly stable over the course of the study regardless of treatment group, with no significant change in memory B cells. Blockade of TNF and LT with etanercept compared to blockade of TNF alone with adalimumab did not translate into significant differences in clinical response. The frequencies of multiple activated B cell populations, including CD21- double-negative memory and activated naive B cells, were higher in RA nonresponders at all time points, and CD95+ activated B cell frequencies were increased in patients receiving anti-TNF treatment in the nonresponder group. In contrast, frequencies of transitional B cells-a putative regulatory subset-were lower in the nonresponders.

conclusionOverall, our results support the notion that peripheral blood B cell subsets are remarkably stable in RA and not differentially impacted by dual blockade of TNF and LT with etanercept or single blockade of TNF with adalimumab. Activated B cells do associate with a less robust response.

Indexed as

AdalimumabAdultAgedAntirheumatic AgentsArthritis, RheumatoidB-LymphocytesEtanerceptFemaleHumansMaleMiddle AgedSingle-Blind MethodTumor Necrosis Factor InhibitorsAdalimumabAntirheumatic AgentsEtanerceptTumor Necrosis Factor Inhibitors

Identifiers

PMID34347945
PMCPMC8795463
OpenAlexW3193121651

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.